Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,623 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04752826RecruitingPhase 1/Phase 2
Testing BI-1808 plus Keytruda for advanced cancers
This trial tests a new cancer medicine (BI-1808) either alone or together with Keytruda (pembrolizumab) in people with advanced cancers. It may help by strengthening the immune system’s attack on cancer, especially if standard treatments are no longer working or aren’t suitable.
Duarte, CaliforniaAges 18 years+ - NCT04766515Recruiting
Study of immune checkpoint cancer treatment in real life
This is an observational study that follows adults with solid cancer who are receiving immune checkpoint inhibitor treatments. It aims to learn how these medicines are used and what outcomes may look like in everyday care.
ShanghaiAges 18 years+ - NCT04771806Recruiting
MRI-guided adaptive radiation for high-grade brain tumors
This study uses repeated MRI scans with a contrast dye to help doctors tailor (adapt) your radiation treatment over time for a high-grade glioma. It may help improve how accurately radiation targets the tumor as it changes.
Houston, TexasAges 18 years+ - NCT04807673RecruitingPhase 3
Pembrolizumab before surgery versus chemoradiation for esophageal cancer
This Phase 3 study compares two treatment plans before surgery for locally advanced esophageal squamous cell carcinoma. It tests whether adding pembrolizumab (an immune therapy) to chemotherapy improves outcomes compared with standard chemoradiation.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT04807114Recruiting
Blood or tissue testing to find markers for lung cancer treatment
This study uses detailed “single-cell” testing to look for markers that can predict how well immunotherapy works and what side effects may happen. It is for people with non-small cell lung cancer starting standard first-line treatment.
LeuvenAges 18–120 - NCT04808323RecruitingPhase 1
MRI-guided radiation to help preserve organs in rectal cancer
This Phase 1 study tests a radiation treatment approach guided by MRI scans to help keep nearby organs functioning while treating rectal cancer. It is designed to find a safe, effective way to target the tumor and adjust treatment during the course of therapy.
Milwaukee, WisconsinAges 18 years+ - NCT04808596Recruiting
Pulmonary hypertension registry and blood sample study
This study builds a registry and collection system for people with pulmonary hypertension, confirmed by a specific heart test. By joining, you help researchers learn more about the condition and may support future studies.
Kansas City, KansasAges 18 years+ - NCT04815356RecruitingPhase 1
T cells designed to attack a blood cancer called hairy cell leukemia
This early-stage (Phase 1) study tests a new type of treatment made from your T cells (immune cells) that are programmed to find and kill cancer cells with a specific marker (CD22). It’s designed for people with hairy cell leukemia that has come back or didn’t respond to prior treatments, and it aims to see safety and how well the approach works.
Bethesda, MarylandAges 18 years+ - NCT04823403RecruitingPhase 1
Targeted liver delivery of immunotherapy for advanced liver cancer
This early-phase study tests how well giving ipilimumab directly into the liver (via an artery) and nivolumab through a vein works for advanced hepatocellular carcinoma (liver cancer). It is for people whose cancer cannot be removed with surgery or treated with a transplant, especially after standard treatment failed or wasn’t tolerated.
VillejuifAges 18 years+ - NCT04830267RecruitingPhase 2
Camrelizumab plus focused radiation for recurrent metastatic nasopharyngeal cancer
This Phase 2 trial studies whether adding camrelizumab (an immune medicine) to stereotactic body radiation (focused, high-precision radiation) helps people with recurrent or metastatic nasopharyngeal cancer. It aims to improve control of the cancer (and may use blood EBV levels to help track response).
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT04850729Recruiting
Study links surgery medicines to the stomach tumor environment
This trial looks at how medicines given around the time of stomach cancer surgery may change the “tumor microenvironment,” which is the biology around the tumor. It may help doctors better understand which perioperative treatments work best for locally advanced, operable stomach cancer.
Guangzhou, GuangdongAges 18–75 - NCT04855435RecruitingPhase 1
Study drug for advanced melanoma and other solid tumors
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
HerlevAges 18 years+ - NCT04858256RecruitingPhase 2
Pacritinib for relapsed or resistant T-cell blood cancers
This Phase 2 trial studies pacritinib, an oral medicine, for T-cell lymphoma/leukemia that has come back or did not respond to prior treatment. It aims to see how well pacritinib can control the cancer and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT04868604RecruitingPhase 1/Phase 2
Copper PSMA scan and treatment for prostate cancer in men on low testosterone
This trial tests a PSMA-targeted copper medicine used after a special PSMA PET/CT scan to find and treat prostate cancer that has spread. It’s for men whose testosterone is already very low and whose cancer is growing despite hormone-blocking medicines like enzalutamide or abiraterone.
Stanford, CaliforniaAges 18 years+ - NCT04872543RecruitingPhase 2
Study drug for nerve tumor caused by PRC2 loss
This Phase 2 trial studies ASTX727 in people with malignant peripheral nerve sheath tumors (MPNST) that have a specific genetic change (“PRC2 loss”). It aims to shrink or control advanced tumors that have not responded to at least one standard treatment, by testing how well the drug works and is tolerated.
Basking Ridge, New JerseyAges 16 years+ - NCT04878029RecruitingPhase 1
Cabozantinib plus enfortumab for advanced bladder cancer after immunotherapy
This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.
Atlanta, GeorgiaAges 18 years+ - NCT04883671Recruiting
SBRT to treat a few spots of adenoid cystic cancer
This trial tests whether focused radiation (SBRT) can help control adenoid cystic carcinoma that has spread to a small number of places (oligometastatic disease). If you qualify, the study will treat up to 1–5 metastatic spots that doctors think can be safely targeted, to help control the cancer locally.
San Francisco, CaliforniaAges 18 years+ - NCT04889716RecruitingPhase 2
CAR-T followed by antibody treatment for lymphoma
This Phase 2 study looks at giving CAR-T cell therapy first, then follow-up “bispecific” antibody medicines to help keep large B-cell lymphoma from coming back. It’s for people whose lymphoma returned or did not respond to prior standard treatments and who still have measurable disease on scans.
Omaha, NebraskaAges 18 years+ - NCT04891289RecruitingPhase 2
Gemcitabine and oxaliplatin with a chemotherapy pump for bile duct cancer
This Phase 2 study tests gemcitabine plus oxaliplatin chemotherapy, and whether adding a chemotherapy pump (with floxuridine and dexamethasone) delivered to the liver improves outcomes. It is for people whose intrahepatic cholangiocarcinoma cannot be removed with surgery.
Bethesda, MarylandAges 18 years+ - NCT04896801Recruiting
MRI-guided radiation for certain prostate cancer risks
This trial tests a precise, MRI-guided radiation treatment given over 7 days for people with prostate cancer in specific risk categories. It may help shrink or control the cancer while carefully targeting the tumor.
BrusselsAges 18 years+ - NCT04900623RecruitingPhase 2
Using HPV blood test to guide treatment for HPV throat cancer
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Boston, MassachusettsAges 22 years+ - NCT04902443RecruitingPhase 1
Pomalidomide plus nivolumab for virus-related cancers
This trial studies pomalidomide plus nivolumab in people with cancers linked to certain viruses (or hepatitis B/C). It may help the immune system fight the cancer when the disease has returned, progressed, or can’t be fully treated with standard options.
Bethesda, MarylandAges 18–99 - NCT04920032RecruitingPhase 1
Blood test–guided extra treatment for colon cancer recurrence risk
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
Orange, CaliforniaAges 18 years+ - NCT04927897Recruiting
Testing where to aim extra rectal radiation before surgery
This trial tests the best place to target an “extra boost” of radiation inside the rectum for certain rectal cancer patients. It may help guide more precise treatment planning before they have total mesorectal excision (TME) surgery.
Maastricht, LimburgAges 18 years+
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,623 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.